The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2002 Release

December 20, 2002 Notice Concerning Subsidiary Dissolution
December 11, 2002 Eisai Launches SKAINAR(R) COOL FOR RHINITIS and
SKAINAR(R) SPRAY FOR RHINITIS for Allergic and Acute Rhinitis
November 14, 2002 ACIPHEX(R) , Proton Pump Inhibitor, First Seven-Day Treatment of H.pylori Infection Approved by FDA
November 13, 2002 Eisai transfers Veterinary and Livestock Feed Products Business to Meiji Seika
November 5, 2002 Eisai Submits Vascular Dementia Marketing Authorization Application for ARICEPT (R) in the U.K.
October 24, 2002 Neurogenetics, Inc. Extends Agreement With Eisai Co., Ltd.
October 17, 2002 Eisai Launches DENTAKE(R) DENTAL RINSE and DENTAKE(R) MEDICATED TOOTH PASTE for Prevention against Periodontal Diseases
October 10, 2002 Environmental Study Results of Eisai Site in Funado, Itabashi-ku
October 4, 2002 Eisai Launches SACLON (R) FRESH Drink Refreshing Relief from Upset Stomach
October 4, 2002 Eisai Launches BREATHE RIGHT (R) KIDS TYPE Nasal Strips for Children of Age 5-12
September 4, 2002 Eisai Submits sNDA for ARICEPT (R) for Treatment of Vascular Dementia (VaD)
August 20, 2002 Notice Concerning Acquisition of the Company's Own Shares in the Market
August 20, 2002 Eisai Launches JUVELUX(R)L For Relief of Hot and Cold Flashes Associated with Menopause
July 25, 2002 Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., to Promote a Pfizer Product
July 2, 2002 Eisai Launches TRAVELMIN(R) FAMILY
- A Motion Sickness Medication That Dissolves Quickly In The Mouth -
July 1, 2002 Notice Concerning Stock Options Including the Amount to Be Paid for the Exercise of Stock Options
June 27, 2002 Notice of Allotment of Stock Options
May 14, 2002 Notice Concerning Acquisition of the Company's Own Shares in the Market
May 14, 2002 Notice on Providing Stock Options in the Form of New Stock Issuance
May 14, 2002 Eisai Establishes Clinical Research Subsidiary in the United States
April 17, 2002 Vascular Dementia Phase III Clinical Trial Results for ARICEPT (R), an ALZHEIMER'S Disease Treatment, Announced at an Academic Conference
March 26, 2002 Eisai Announces the Merger of Six Japan-based Subsidiaries
March 20, 2002 Aventis Pharma Ltd. and Eisai Co., Ltd. Announce Copromotion Agreement for the Osteoporosis Therapeutic Agent, ACTONEL(R) 2.5 mg
February 25, 2002 Notice of Acquisition Completion of the Company's Own Shares through ToSTNeT-2
February 22, 2002 Notice Concerning Acquisition of the Company's Own Shares in the Market
February 22, 2002 Notice of Acquisition of the Company's Own Shares through ToSTNeT-2
February 22, 2002 Notice of Revision of Forecast Year End Dividend For Fiscal Year Period (90th Company Fiscal Period) Ending March 2002
February 21, 2002 Eisai S.A. in France Acquires All Shares of BIODIM S.A.S.
February 15, 2002 ACIPHEX(R) Receives Approval for the Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) in the U.S.
January 25, 2002 Vascular Dementia Phase III Clinical Trial Results for Aricept(R), an Alzheimer's Disease Treatment, Announced at an Academic Conference
January 16, 2002 Eisai Files Application for a New Indication for ACIPHEX(R) in the U.S. For H. Pylori Eradication
January 7, 2002 Eisai Files Application for Indication Expansion in Japan for PARIET (R)

Back to Top